Veru Inc.'s Enobosarm Shows Promise in Treating Obesity and Preserving Lean Mass
On August 10, 2026, Veru Inc. hosted its quarterly earnings call, where the company provided updates on its clinical development progress and financial highlights for the third quarter of fiscal year 2026.
The main focus of the conference call was on the company's drug enobosarm, a selective androgen receptor modulator (SARM) being developed as a next-generation treatment for obesity. Dr. Mitchell Steiner, Chairman, CEO, and President of Veru Inc., explained that the current GLP-1 receptor agonist treatments for weight loss have significant side effects, including the indiscriminate loss of both lean mass and fat mass.
Veru's enobosarm is being developed to preserve lean mass while promoting fat loss when combined with a GLP-1 receptor agonist. The company has completed a Phase IIb clinical trial, known as QUALITY, which aimed to evaluate the safety and efficacy of enobosarm in augmenting fat loss and preventing muscle loss in older patients with obesity.
The results of the study were promising, showing that enobosarm treatment preserved lean mass and reduced the proportion of patients experiencing a clinically significant decline in physical function. Dr. Steiner noted that this was the first human study to demonstrate the risk of accelerated lean mass loss and physical function decline in older patients with obesity receiving GLP-1 receptor agonist treatment alone.
According to Veru Inc., the data from the QUALITY clinical trial demonstrated that enobosarm has the potential to provide a more targeted approach to weight reduction, preserving muscle mass and physical function while promoting fat loss. This could lead to improved patient outcomes and quality of life for those with obesity.
The company also provided financial highlights for the third quarter of fiscal year 2026, which will be reported in their quarterly earnings press release. Veru's focus on developing innovative treatments like enobosarm reflects its commitment to improving patient care and addressing unmet medical needs.
With a late clinical stage biopharmaceutical company, Veru Inc. continues to push the boundaries of what is possible in the treatment of cardiometabolic and inflammatory diseases. The success of enobosarm could have significant implications for patients with obesity and those at risk of sarcopenia, making it an exciting area of research.
